Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its... see more

Recent & Breaking News (TSXV:KNE)

Kane Biotech Announces Amendment to its Credit Facility

GlobeNewswire March 2, 2023

Kane Biotech Announces Proposed Amendments to its Credit Facility and Changes to its Board of Directors

GlobeNewswire March 1, 2023

Kane Biotech’s Coactiv+™ Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation

TheNewsWire February 6, 2023

Kane Biotech Announces Extension of Term of Credit Facility

GlobeNewswire February 6, 2023

Kane Biotech Announces First Distribution Agreement for its coactiv+(TM) Antimicrobial Hydrogel

GlobeNewswire January 4, 2023

Kane Biotech Announces Loan Transaction

GlobeNewswire December 29, 2022

Kane Biotech Announces Third Quarter 2022 Financial Results

GlobeNewswire November 24, 2022

Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 - Conference Call to Follow

GlobeNewswire November 17, 2022

Kane Biotech Announces 510(k) Submission for its coactiv+(TM) Antimicrobial Hydrogel

GlobeNewswire November 3, 2022

Kane Biotech to Present at Symposium on Advanced Wound Care Fall Forum

GlobeNewswire October 13, 2022

Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense

GlobeNewswire October 4, 2022

Kane Biotech Announces Second Quarter 2022 Financial Results

GlobeNewswire August 25, 2022

Kane Biotech to Release Second Quarter 2022 Financial Results on August 25, 2022 - Conference Call to Follow

GlobeNewswire August 18, 2022

Kane Biotech Announces Adoption of Amended and Restated Stock Option Plan and Performance and Restricted Share Unit Plan

GlobeNewswire June 30, 2022

Kane Biotech Announces Amended Credit Facility

GlobeNewswire June 15, 2022

Kane Biotech Announces First Quarter 2022 Financial Results

GlobeNewswire May 26, 2022

Kane Biotech to Release First Quarter 2022 Financial Results on May 26 - Conference Call to Follow

GlobeNewswire May 19, 2022

Kane Biotech Inc. (TSXV:KNE) obtains ISO 13485 certification

Shoran Devi May 18, 2022

Kane Biotech Obtains ISO 13485 Certification

GlobeNewswire May 18, 2022

Kane Biotech (TSXV:KNE) closes private placement

John Ballem  May 17, 2022